Search Results

You are looking at 31 - 40 of 931 items for :

  • "NCCN Clinical Practice Guidelines in Oncology NCCN Guidelines" x
  • Refine by Access: All x
Clear All
Full access

Kilian E. Salerno

In the most recent NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Breast Cancer, there were updates pertaining to various radiation treatment options, including whole-breast radiotherapy (RT), accelerated partial

Full access

Presenter: Ronald S. Go

“Histiocytoses are rare diseases, and the annual incidences…are not exactly known,” revealed Ronald S. Go, MD, Associate Professor of Medicine, Mayo Clinic, Rochester, and panel chair of the NCCN Clinical Practice Guidelines in Oncology (NCCN

Full access

Kaylene Ready and Banu Arun

. Families such as these are often managed as if they have a known hereditary breast cancer syndrome, because the family history is so compelling. The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Genetic/Familial High-Risk Assessment

Full access

Leora Horn

Conference, joining maintenance chemotherapy and treatment of patients with acquired resistance to tyrosine kinase therapy with newer generation inhibitors. Chemotherapy: Histology Guides Choices According to the 2014 NCCN Clinical Practice Guidelines

Full access

Philippe E. Spiess

Practice Guidelines in Oncology (NCCN Guidelines) for penile cancer, with input from experts in penile cancer from around the world. This comprehensive protocol is intended to establish a foundation to help standardize and optimize the care of patients

Full access

Ali Bazarbachi, Hamdy A. Azim, Hussain Alizadeh, Mahmoud Aljurf, Ibrahim Barista, Naeem A. Chaudhri, Zahira Fahed, Omar A. Fahmy, Ardeshir Ghavamzadeh, Mohamed H. Khalaf, Sami Khatib, Aghiad Kutoubi, Semra Paydas, Hanadi Rafii Elayoubi, Ghazi Zaatari, Hamdy M. Zawam, and Andrew D. Zelenetz

NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) on Non-Hodgkin's Lymphoma and the 2008 version of the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) on Hodgkin Lymphoma (to view the most recent version of these

Full access

Fikri İçli, Hakan Akbulut, Shouki Bazarbashi, Mehmet Ayhan Kuzu, Mohandas K. Mallath, Kakil Ibrahim Rasul, Scott Strong, Aamir Ali Syed, Faruk Zorlu, and Paul F. Engstrom

Colorectal cancer is less common in the Middle East and South Asia than in western countries, with the rectum the most common primary site, unlike in the United States. A project was planned to address various local issues regarding the management of common cancers, including colorectal cancer, and to adapt the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) to the Middle East and North Africa (MENA) region. A survey of oncologists in this geographic area showed that the management practices and issues regarding colorectal cancer are similar to those presented in the NCCN Colorectal Cancer Guidelines. However, 2 major differences exist: most oncologists in the MENA region prefer chest radiograph over CT in pretreatment workup, and almost 50% of them prefer to use cetuximab in the first-line treatment of patients with the wild-type KRAS gene. The committee, comprising 9 oncologists from different countries, proposed 4 modifications to the 2009 version of the NCCN Colorectal Cancer Guidelines for use in the MENA region, relating to 1) short-course preoperative radiotherapy, 2) dose of capecitabine, 3) stereotactic radiotherapy for liver metastasis, and 4) qualification of surgeons performing colorectal surgery. The modification of NCCN Colorectal Cancer Guidelines for use in the MENA region represents a step toward creating a uniform practice in the region based on evidence and local experience.

Full access

Presenter: Aaron T. Gerds

expectancy, with an average time from diagnosis to death of approximately 5 to 6 years in all-comers,” he stated. Disease Risk Assessment Unlike many of the solid tumors represented in the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines), the

Full access

Metastatic Breast Cancer, Version 1.2012

Featured Updates to the NCCN Guidelines

Robert W. Carlson, D. Craig Allred, Benjamin O. Anderson, Harold J. Burstein, Stephen B. Edge, William B. Farrar, Andres Forero, Sharon Hermes Giordano, Lori J. Goldstein, William J. Gradishar, Daniel F. Hayes, Clifford A. Hudis, Steven Jay Isakoff, Britt-Marie E. Ljung, David A. Mankoff, P. Kelly Marcom, Ingrid A. Mayer, Beryl McCormick, Lori J. Pierce, Elizabeth C. Reed, Mary Lou Smith, Hatem Soliman, George Somlo, Richard L. Theriault, John H. Ward, Antonio C. Wolff, Richard Zellars, Rashmi Kumar, and Dorothy A. Shead

Guidelines in Oncology (NCCN Guidelines) for Breast Cancer include up-to-date guidelines for the clinical management of patients with carcinoma in situ, invasive breast cancer, Paget disease, Phyllodes tumor, inflammatory breast caner, and breast cancer

Full access

Jennifer L. Schwartz, Sandra L. Wong, Scott A. McLean, James A. Hayman, Christopher D. Lao, Jeffrey H. Kozlow, Kelly M. Malloy, Carol R. Bradford, Marcus L. Frohm, Douglas R. Fullen, Lori Lowe, and Christopher K. Bichakjian

limitations. This article discusses the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for MCC, including the importance of multidisciplinary management, and highlights the implementation of these guidelines in the multidisciplinary MCC